The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans

The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans

Background: Evaluating long-term efficacy, safety and pharmacokinetics of long-acting cabotegravir + rilpivirine (CAB+RPV LA) in sub-Saharan African populations is important because of the region’s unique demographics and antiretroviral therapy resistance patterns. Objectives: To describe the 96-we...

Full description

Saved in:
Bibliographic Details
Main Authors: Rosie Mngqibisa, Yashna Singh, Catherine Orrell, Johan Lombaard, Sandy Griffith, Conn Harrington, Ronald D’Amico, William Spreen, Marty St Clair, Christine Latham, Louise Garside, Rodica Van Solingen-Ristea, Veerle Van Eygen, Fafa Addo Boateng, Herta Crauwels, Prosperity Eneh, Ingrid Eshun-Wilsonova
Format: Article
Language:English
Published: AOSIS 2025-07-01
Series:Southern African Journal of HIV Medicine
Subjects:
clinical trials
phase 3
viral suppression
resistance
treatment
africa
adherence
arv
Online Access:https://sajhivmed.org.za/index.php/hivmed/article/view/1709
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://sajhivmed.org.za/index.php/hivmed/article/view/1709

Similar Items